AGMB
AgomAb Therapeutics NV
NASDAQ · Healthcare · Biotechnology · BE
$12.17
+0.75%Next report
Analyst consensus
- Next report date
- Mar 3, 2027
- EPS estimate
- -$0.97
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.91
- EPS estimate
- -$0.38
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 0
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -72.2%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $43
- PT range
- $34 – $60
- Analysts
- 4
4 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.38 | -$0.91 | Miss -137.55% | — |
| Jun 3, 2026 | -$0.42 | -$0.45 | Miss -6.76% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Mar 3, 2027